Sepsis Diagnostics Market by Technology (Microbiology, PCR, Microarray, Immunoassay, Biomarkers), Product (Reagents, Assay, Instruments, Software), Method, Test Type (Lab, POC), Pathogen (Bacterial, Fungal), End User and Region - Global Forecast to 2025
Get in-depth analysis of the COVID-19 impact on the Sepsis Diagnostics Market
Benchmarking the rapid strategy shifts of the Top 100 companies in the Sepsis Diagnostics Market
Request For Special Pricing[199 Pages Report] The global sepsis diagnostics market size is expected to reach USD 700 million by 2025 from USD 429 million in 2019, at a CAGR of 8.5%. The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the increasing public-private funding for target research activities, the growing burden of infectious diseases, the rising number of sepsis incidences, and growing government initiatives for creating sepsis awareness.
The blood culture segment accounted for the largest share of the market, by technology, in 2019
The sepsis diagnostics market, by technology, the market is segmented into blood culture, immunoassays, molecular diagnostics, flow cytometry, microfluidics, and biomarkers. In 2019, the blood culture segment accounted for the largest share of the market. This share can be attributed to the low cost of microbiology techniques and the extensive use of blood culture methods for the diagnosis of sepsis.
The hospitals end-user segment accounted for the largest share of the sepsis diagnostics market in 2019
Based on end-user, the market is segmented into hospitals, pathology & reference laboratories, and research laboratories & academic institutes. In 2019, hospitals accounted for the largest share of the sepsis diagnostics industry. The large share of this segment can be attributed to the high prevalence of sepsis coupled with a large number of fatalities caused by the illness, and in-house hospital laboratories perform a large number of blood culture tests to identify BSIs (caused by bacteria, fungi/yeast, or viruses).
North America accounted for the largest share of the global sepsis diagnostics market in 2019
North America is a well-established market for medical devices. The presence of a highly developed healthcare system, high adoption of innovative sepsis diagnostic technologies among medical professionals, increasing sepsis incidences performed in the region, and technological advancements in the field of sepsis diagnostics are the major factors driving the market in North America.
Key Market Players
Some of the players in the sepsis diagnostics market are bioMιrieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US). An analysis of the market developments between 2016 and 2019 revealed that product launches & enhancements, partnerships, agreements, and acquisitions were adopted by market players to strengthen their product portfolios and maintain a competitive position in the market. Product launches were the most widely adopted growth strategies.
BioMerieux is the top player in the global sepsis diagnostics market. The company has been focusing on new product development and product approvals in the field of sepsis diagnostics. In addition, the company has a strong global presence with strong distribution channels to serve markets in North America, Europe, Oceania, Africa, and Asia Pacific. The company also tries to evaluate new, emerging, and complementary technologies to identify new product opportunities.
Scope of the Report
|
Report Metric |
Details |
|
Market size available for years |
20172025 |
|
Base year considered |
2018 |
|
Forecast period |
20192025 |
|
Forecast units |
Value (USD) |
|
Segments covered |
Technology, product, method, pathogen, test type, end-user, and region |
|
Geographies covered |
North America (US and Canada), Europe (Germany, France, UK, Spain, Italy, and the Rest of Europe), Asia Pacific (China, Japan, Australia, India, South Korea, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of LATAM), and the Middle East and Africa |
|
Companies covered |
Major players covered include bioMιrieux (France), Becton Dickinson Company (US), Danaher (US), Abbott Laboratories (US), Roche Diagnostics (Switzerland), T2 Biosystems (US), Luminex (US), Thermo Fisher Scientific (US), Bruker (US), EKF Diagnostics (UK), Immunexpress (Australia), Response Biomedical (Canada), Axis-Shield Diagnostics (UK), and CytoSorbents (US). |
This research report categorizes the sepsis diagnostics market into the following segments and subsegments:
By Technology
- Blood Culture
- Immunoassays
- Molecular Diagnostics
- PCR
- Peptide Nucleic Acid-Fluorescent In Situ Hybridization
- Microarrays
- Syndromic Panel-Based Testing
- Flow Cytometry
- Microfluidics
- Biomarkers
By Product
- Blood Culture Media
- Assays & Reagents
- Instruments
- Software
By Method
- Automated Diagnostics
- Conventional Diagnostics
By Pathogen
- Bacterial Sepsis
- Gram-Negative Bacterial Sepsis
- Gram-Positive Bacterial Sepsis
- Fungal Sepsis
- Other Pathogen
By Test Type
- Laboratory Tests
- Point-of-Care Tests
By End-User
- Hospitals
- Pathology & Reference Laboratories
- Research Laboratories & Academic Institutes
By Region
- North America
- US
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- RoE
- Asia Pacific
- China
- Japan
- Australia
- South Korea
- India
- RoAPAC
- Latin America
- Brazil
- Mexico
- RoLATAM
- Middle East & Africa
Recent Developments (2016-2019):
- In September 2019, T2 Biosystems launched T2 Resistance Panel
- In September 2019, T2 Biosystems entered into an agreement with BioNuclear Puerto Rico to expand its distribution of rapid diagnostic technologies, including the T2Bacteria and T2Candida Panels, in Puerto Rico and the US Virgin Islands
- In December 2018, BioMerieux (France) received FDA approval for BPA and BPN used with BACT/ALERT VIRTUO for quality control testing of platelets
- In November 2018, BioMerieux (France) received FDA clearance and CE approval for BIOFIRE FILMARRAY Pneumonia Panels
- In September 2016, Danaher acquired Cepheid To expand its molecular diagnostics product portfolio
Key Questions Addressed by the Report:
- What are the growth opportunities related to the adoption of sepsis diagnostic products across significant regions in the future?
- Emerging countries show immense opportunities for the growth and adoption of sepsis diagnostic instruments, related reagents & consumables, and software. Will this scenario continue in the next five years?
- Where will the advancements in products offered by various companies take the industry in the mid- to long-term?
- What are the newest trends and advancements in the sepsis diagnostics market?
- What initiatives are companies undertaking to sustain in the market, especially through uncertain situations such as the COVID-19 pandemic?
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 19)
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 STAKEHOLDERS
2 RESEARCH METHODOLOGY (Page No. - 22)
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Secondary sources
2.1.2 PRIMARY DATA
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
2.2.2 PROCEDURE-BASED MARKET ESTIMATION
2.2.3 PRIMARY RESEARCH VALIDATION
2.3 DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
3 EXECUTIVE SUMMARY (Page No. - 31)
4 PREMIUM INSIGHTS (Page No. - 36)
4.1 SEPSIS DIAGNOSTICS: MARKET OVERVIEW
4.2 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY
4.3 GEOGRAPHIC ANALYSIS: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT AND REGION
4.4 APAC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY AND END USER
4.5 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN
4.6 GEOGRAPHIC SNAPSHOT OF THE SEPSIS DIAGNOSTICS MARKET
5 MARKET OVERVIEW (Page No. - 40)
5.1 INTRODUCTION
5.2 MARKET DINAMICS
5.2.1 DRIVERS
5.2.1.1 High incidence of sepsis
5.2.1.2 Rising incidence of hospital-acquired infections
5.2.1.3 Growing funding for sepsis-related research
5.2.2 RESTRAINTS
5.2.2.1 Unfavorable reimbursement scenario
5.2.2.2 High cost of automated diagnostic devices
5.2.3 OPPORTUNITIES
5.2.3.1 Development of rapid diagnostic/POC techniques for early sepsis diagnosis
5.2.3.2 Evolution of novel biomarkers for sepsis diagnosis
5.2.4 CHALLENGES
5.2.4.1 Lack of standard protocols and awareness
5.2.4.2 Shortage of skilled healthcare professionals
6 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY (Page No. - 46)
6.1 INTRODUCTION
6.2 BLOOD CULTURE
6.2.1 BLOOD CULTURE HOLDS THE LARGEST SHARE OF THE TECHNOLOGY MARKET
6.3 IMMUNOASSAYS
6.3.1 PRODUCT DEVELOPMENT EFFORTS BY MAJOR PLAYERS HAVE ENSURED DEMAND FOR IMMUNOASSAYS
6.4 MOLECULAR DIAGNOSTICS
6.4.1 POLYMERASE CHAIN REACTION
6.4.1.1 PCR holds the largest share of the molecular diagnostics market
6.4.2 MICROARRAYS
6.4.2.1 Simultaneous analysis capabilities, accuracy, and rapidity have driven the use of microarrays
6.4.3 PEPTIDE NUCLEIC ACID-FLUORESCENT IN SITU HYBRIDIZATION
6.4.3.1 PNA-FISH kits allow for the rapid diagnosis of BSIs
6.4.4 SYNDROMIC PANEL-BASED TESTING
6.4.4.1 High costs and accuracy issues have affected test adoption
6.5 FLOW CYTOMETRY
6.5.1 LACK OF STANDARDIZED PROTOCOLS IS A KEY RESTRAINT IN THIS MARKET SEGMENT
6.6 MICROFLUIDICS
6.6.1 GROWING ADOPTION OF ADVANCED & RAPID TESTING WILL FAVOR MARKET GROWTH IN THIS SEGMENT
6.7 BIOMARKERS
6.7.1 DESPITE POTENTIAL, NO SINGLE IDEAL BIOMARKER HAS BEEN IDENTIFIED FOR SEPSIS DIAGNOSTICS
7 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT (Page No. - 71)
7.1 INTRODUCTION
7.2 BLOOD CULTURE MEDIA
7.2.1 BLOOD CULTURE MEDIA DOMINATE THE PRODUCTS MARKET
7.3 ASSAYS & REAGENTS
7.3.1 INCREASING AWARENESS HAS DRIVEN THE USE OF ASSAYS & REAGENTS
7.4 INSTRUMENTS
7.4.1 MARKET IS CHARACTERIZED BY A SHIFT FROM TRADITIONAL & MANUAL INSTRUMENTS TO AUTOMATED SYSTEMS
7.5 SOFTWARE
7.5.1 RISING USE OF AUTOMATED INSTRUMENTS WILL ENSURE DEMAND FOR SOFTWARE
8 SEPSIS DIAGNOSTICS MARKET, BY METHOD (Page No. - 76)
8.1 INTRODUCTION
8.2 CONVENTIONAL DIAGNOSTICS
8.2.1 CONVENTIONAL DIAGNOSTICS HOLDS LARGEST MARKET SHARE
8.3 AUTOMATED DIAGNOSTICS
8.3.1 AUTOMATED DIAGNOSTICS SEGMENT TO GROW AT THE HIGHEST CAGR
9 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN (Page No. - 80)
9.1 INTRODUCTION
9.2 BACTERIAL SEPSIS
9.2.1 GRAM-NEGATIVE BACTERIAL SEPSIS
9.2.1.1 Gram-negative bacteria cause ~50% of sepsis infections
9.2.2 GRAM-POSITIVE BACTERIAL SEPSIS
9.2.2.1 Cases of sepsis caused by gram-positive bacteria have risen in recent years
9.3 FUNGAL SEPSIS
9.3.1 FUNGEMIA IS THE SECOND-BIGGEST CAUSE OF BLOODSTREAM INFECTIONS
9.4 OTHER PATHOGENS
10 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 86)
10.1 INTRODUCTION
10.2 LABORATORY TESTS
10.2.1 LABORATORY TESTS ARE THE MOST COMMON AND PREFERRED MODE OF TESTING
10.3 POINT-OF-CARE TESTS
10.3.1 RAPIDITY AND CONVENIENCE HAVE DRIVEN DEMAND FOR POC TESTS
11 SEPSIS DIAGNOSTICS MARKET, BY END USER (Page No. - 90)
11.1 INTRODUCTION
11.2 HOSPITALS
11.2.1 HOSPITALS HOLD THE LARGEST SHARE OF THE SEPSIS DIAGNOSTICS MARKET
11.3 PATHOLOGY & REFERENCE LABORATORIES
11.3.1 INDEPENDENT LABORATORIES OFFER AFFORDABILITY AS WELL AS THE BENEFITS OF BUNDLED SERVICES
11.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
11.4.1 GOVERNMENT SUPPORT AND RISING AWARENESS HAVE ENSURED DEMAND FOR MARKET PRODUCTS IN THIS SEGMENT
12 SEPSIS DIAGNOSTICS MARKET, BY REGION (Page No. - 94)
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 US
12.2.1.1 US is the largest market for sepsis diagnostics
12.2.2 CANADA
12.2.2.1 Growing availability of sepsis diagnostic products to support market growth in Canada
12.3 EUROPE
12.3.1 GERMANY
12.3.1.1 Germany accounted for the largest share of the European market
12.3.2 FRANCE
12.3.2.1 High incidence and rising awareness have supported the demand for sepsis diagnostics in France
12.3.3 UK
12.3.3.1 Government support and rising awareness are key drivers in the UK
12.3.4 ITALY
12.3.4.1 Sluggish growth in the Italian healthcare sector in the last few years to restrain the market growth
12.3.5 SPAIN
12.3.5.1 Rising sepsis incidence to drive market growth in Spain
12.3.6 REST OF EUROPE
12.4 ASIA PACIFIC
12.4.1 JAPAN
12.4.1.1 Significant growth in pneumonia and infectious disease incidence to support market growth in Japan
12.4.2 CHINA
12.4.2.1 Healthcare infrastructure improvements to support market growth in China
12.4.3 INDIA
12.4.3.1 Increasing patient population and rising number of surgical procedures are key growth drivers in India
12.4.4 AUSTRALIA
12.4.4.1 Increasing number of sepsis treatment procedures indicates growth potential in the Australian market
12.4.5 SOUTH KOREA
12.4.5.1 Rising healthcare spending supports market growth in South Korea
12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
12.5.1 BRAZIL
12.5.1.1 Brazil accounted for the largest share of the LATAM market
12.5.2 MEXICO
12.5.2.1 Rising medical tourism to support market growth in Mexico
12.5.3 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
12.6.1 HIGH CONSUMPTION OF IMMUNE SYSTEM-SUPPRESSING MEDICATIONS IS DRIVING SEPSIS OCCURRENCE
13 COMPETITIVE LANDSCAPE (Page No. - 135)
13.1 OVERVIEW
13.2 MARKET SHARE ANALYSIS
13.3 COMPETITIVE SCENARIO
13.3.1 PRODUCT LAUNCHES AND APPROVALS, 20162020
13.3.2 PARTNERSHIPS AND COLLABORATIONS, 20162020
13.3.3 MERGERS AND ACQUISITIONS, 20162020
13.3.4 MARKET EXPANSION, 20162020
13.4 COMPETITIVE LEADERSHIP MAPPING
13.4.1 VISIONARY LEADERS
13.4.2 INNOVATORS
13.4.3 DYNAMIC DIFFERENTIATORS
13.4.4 EMERGING COMPANIES
14 COMPANY PROFILES (Page No. - 141)
(Business Overview, Products Offered, Recent Developments, MnM View)*
14.1 BIOMΙRIEUX
14.2 BECTON, DICKINSON AND COMPANY
14.3 DANAHER
14.4 T2 BIOSYSTEMS
14.5 LUMINEX
14.6 ROCHE DIAGNOSTICS
14.7 THERMO FISHER SCIENTIFIC
14.8 BRUKER CORPORATION
14.9 ABBOTT
14.10 IMMUNEXPRESS
14.11 RESPONSE BIOMEDICAL
14.12 AXIS-SHIELD DIAGNOSTICS
14.13 CYTOSORBENTS
14.14 MITSUBISHI CHEMICAL EUROPE
14.15 EKF DIAGNOSTICS
14.16 EMERGING PLAYERS
14.16.1 SEEGENE
14.16.2 GENMARK DIAGNOSTICS
14.16.3 BODITECH MED
14.16.4 ALPHA LABORATORIES
14.16.5 ALIFAX S.R.L.
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
15 APPENDIX (Page No. - 178)
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGE STORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS
LIST OF TABLES (160 Tables)
TABLE 1 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 2 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 3 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 4 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 5 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 6 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 7 BLOOD CULTURE MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 8 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 9 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 10 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 11 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 12 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 13 IMMUNOASSAYS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 14 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 15 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 16 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 17 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 18 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 19 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 20 MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 21 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 22 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 23 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 24 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 25 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 26 PCR MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 27 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 28 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 29 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 30 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 31 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 32 MICROARRAYS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 33 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 34 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 35 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 36 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 37 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 38 PNA-FISH MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 39 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 40 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 41 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 42 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 43 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 44 SYNDROMIC PANEL-BASED TESTING MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 45 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 46 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 47 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 48 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 49 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 50 FLOW CYTOMETRY MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 51 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 52 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 53 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 54 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 55 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 56 MICROFLUIDICS MARKET FOR SEPSIS DIAGNOSIS, BY END USER, 2017 2025 (USD MILLION)
TABLE 57 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY REGION, 20172025 (USD MILLION)
TABLE 58 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY PRODUCT, 20172025 (USD MILLION)
TABLE 59 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY METHOD, 20172025 (USD MILLION)
TABLE 60 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 61 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 62 BIOMARKERS MARKET FOR SEPSIS DIAGNOSTICS, BY END USER, 20172025 (USD MILLION)
TABLE 63 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 20172025 (USD MILLION)
TABLE 64 SEPSIS DIAGNOSTIC BLOOD CULTURE MEDIA MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 65 SEPSIS DIAGNOSTIC ASSAYS & REAGENTS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 66 SEPSIS DIAGNOSTIC INSTRUMENTS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 67 SEPSIS DIAGNOSTIC SOFTWARE MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 68 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 20172025 (USD MILLION)
TABLE 69 CONVENTIONAL DIAGNOSTICS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 70 AUTOMATED DIAGNOSTICS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 71 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 72 BACTERIAL SEPSIS MARKET, BY TYPE, 20172025 (USD MILLION)
TABLE 73 BACTERIAL SEPSIS MARKET, BY REGION, 20192025 (USD MILLION)
TABLE 74 CAUSES OF ADULT SEPSIS: GRAM-NEGATIVE BACTERIA
TABLE 75 GRAM-NEGATIVE BACTERIAL SEPSIS MARKET, BY REGION, 20192025 (USD MILLION)
TABLE 76 CAUSES OF ADULT SEPSIS: GRAM-POSITIVE BACTERIA
TABLE 77 GRAM-POSITIVE BACTERIAL SEPSIS MARKET, BY REGION, 20192025 (USD MILLION)
TABLE 78 FUNGAL SEPSIS MARKET, BY REGION, 20192025 (USD MILLION)
TABLE 79 OTHER PATHOGENS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 80 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 81 LABORATORY SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 82 POINT-OF-CARE SEPSIS DIAGNOSTIC TESTS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 83 SEPSIS DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 84 SEPSIS DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 20172025 (USD MILLION)
TABLE 85 SEPSIS DIAGNOSTICS MARKET FOR PATHOLOGY & REFERENCE LABORATORIES, BY REGION, 20172025 (USD MILLION)
TABLE 86 SEPSIS DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 20172025 (USD MILLION)
TABLE 87 SEPSIS DIAGNOSTICS MARKET, BY REGION, 20172025 (USD MILLION)
TABLE 88 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 89 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 90 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 91 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 20172025 (USD MILLION)
TABLE 92 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 93 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 20172025 (USD MILLION)
TABLE 94 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 95 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 96 US: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 97 US: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 98 CANADA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 99 CANADA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 100 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 101 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 102 EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 103 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 20172025 (USD MILLION)
TABLE 104 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 105 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 20172025 (USD MILLION)
TABLE 106 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 107 EUROPE: SEPSIS DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 108 GERMANY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 109 GERMANY: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 110 FRANCE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 111 FRANCE: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 112 UK: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 113 UK: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 114 ITALY: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 115 ITALY: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 116 SPAIN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 117 SPAIN: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 118 REST OF EUROPE: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 119 REST OF EUROPE: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 120 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 121 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 122 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 123 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 20172025 (USD MILLION)
TABLE 124 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 125 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 20172025 (USD MILLION)
TABLE 126 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 127 ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 128 JAPAN: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 129 JAPAN: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 130 CHINA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 131 CHINA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 132 INDIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 133 INDIA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 134 AUSTRALIA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 135 AUSTRALIA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 136 SOUTH KOREA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 137 SOUTH KOREA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 138 REST OF ASIA PACIFIC: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 139 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 140 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY COUNTRY, 20172025 (USD MILLION)
TABLE 141 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 142 LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 143 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 20172025 (USD MILLION)
TABLE 144 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 145 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 20172025 (USD MILLION)
TABLE 146 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 147 LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
TABLE 148 BRAZIL: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 149 BRAZIL: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 150 MEXICO: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 151 MEXICO: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 152 REST OF LATIN AMERICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 153 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 154 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 20172025 (USD MILLION)
TABLE 155 MIDDLE EAST AND AFRICA: MOLECULAR DIAGNOSTICS MARKET FOR SEPSIS DIAGNOSTICS, BY TECHNIQUE, 20172025 (USD MILLION)
TABLE 156 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 20172025 (USD MILLION)
TABLE 157 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 20172025 (USD MILLION)
TABLE 158 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY METHOD, 20172025 (USD MILLION)
TABLE 159 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 20172025 (USD MILLION)
TABLE 160 MIDDLE EAST AND AFRICA: SEPSIS DIAGNOSTICS MARKET, BY END USER, 20172025 (USD MILLION)
LIST OF FIGURES (36 Figures)
FIGURE 1 RESEARCH DESIGN
FIGURE 2 BREAKDOWN OF PRIMARIES: GLOBAL SEPSIS DIAGNOSTICS MARKET
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
FIGURE 4 MARKET SIZE ESTIMATION: SEPSIS DIAGNOSTICS MARKET
FIGURE 5 DATA TRIANGULATION METHODOLOGY
FIGURE 6 SEPSIS DIAGNOSTICS MARKET, BY PRODUCT, 2019 VS 2025
FIGURE 7 SEPSIS DIAGNOSTICS MARKET, BY TECHNOLOGY, 2019 VS 2025
FIGURE 8 SEPSIS DIAGNOSTICS MARKET, BY METHOD, 2019 VS 2025
FIGURE 9 SEPSIS DIAGNOSTICS MARKET, BY TEST TYPE, 2019 VS 2025
FIGURE 10 SEPSIS DIAGNOSTICS MARKET, BY PATHOGEN, 2019 VS 2025
FIGURE 11 SEPSIS DIAGNOSTICS MARKET, BY END USER, 2018
FIGURE 12 GLOBAL SEPSIS DIAGNOSTICS MARKET, BY REGION, 2019 (USD MILLION)
FIGURE 13 RISING PREVALENCE OF SEPSIS IS DRIVING DEMAND FOR DIAGNOSTICS
FIGURE 14 BLOOD CULTURE SEGMENT WILL DOMINATE THE MARKET DURING 20192025
FIGURE 15 BLOOD CULTURE MEDIA SEGMENT TO DOMINATE THE GLOBAL SEPSIS DIAGNOSTICS PRODUCTS MARKET IN 2019
FIGURE 16 HOSPITALS SEGMENT TO DOMINATE THE ASIA PACIFIC MARKET DURING THE FORECAST PERIOD
FIGURE 17 GRAM-NEGATIVE BACTERIAL SEPSIS HOLDS LARGEST SHARE OF THE GLOBAL MARKET, BY PATHOGEN
FIGURE 18 ASIA PACIFIC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
FIGURE 19 SEPSIS DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 20 NORTH AMERICA: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
FIGURE 21 APAC: SEPSIS DIAGNOSTICS MARKET SNAPSHOT
FIGURE 22 KEY DEVELOPMENTS BY LEADING MARKET PLAYERS IN THE SEPSIS DIAGNOSTICS MARKET, 20162019
FIGURE 23 SEPSIS DIAGNOSTICS MARKET SHARE, BY KEY PLAYERS, 2018
FIGURE 24 SEPSIS DIAGNOSTICS MARKET (GLOBAL) COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 25 BIOMΙRIEUX: COMPANY SNAPSHOT
FIGURE 26 BD: COMPANY SNAPSHOT
FIGURE 27 DANAHER: COMPANY SNAPSHOT
FIGURE 28 T2 BIOSYSTEMS: COMPANY SNAPSHOT (2019)
FIGURE 29 LUMINEX: COMPANY SNAPSHOT
FIGURE 30 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT
FIGURE 31 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
FIGURE 32 BRUKER: COMPANY SNAPSHOT
FIGURE 33 ABBOTT: COMPANY SNAPSHOT
FIGURE 34 CYTOSORBENTS: COMPANY SNAPSHOT
FIGURE 35 MITSUBISHI CHEMICAL EUROPE: COMPANY SNAPSHOT
FIGURE 36 EKF DIAGNOSTICS: COMPANY SNAPSHOT
The study involved four major activities in estimating the current size of the sepsis diagnostics market. Exhaustive secondary research was conducted to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.
Secondary Research
In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Businessweek, and Factiva) were referred to identify and collect information for this study.
Primary Research
The sepsis diagnostics market comprises several stakeholders such as original equipment manufacturers (OEMs), product distributors and channel partners, hospitals, commercial laboratories, and surgical centers, diagnostic laboratories, contract manufacturers and third-party suppliers, research laboratories and academic institutes, clinical research organizations (CROs), government and non-governmental regulatory authorities, and market research and consulting firms. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
A detailed market estimation approach was followed to estimate and validate the value of the sepsis diagnostics market and other dependent submarkets, as mentioned below.
- Key players in the global sepsis diagnostics market were identified through secondary research, and their global market shares were determined through primary and secondary research.
- The research methodology included the study of the annual and quarterly financial reports & regulatory filings of significant market players as well as interviews with industry experts for detailed market insights.
- All percentage shares, splits, and breakdowns for the global sepsis diagnostics market were determined using secondary sources and verified through primary sources.
- All key macro indicators affecting the revenue growth of market segments and subsegments have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the validated and verified quantitative & qualitative data.
- The gathered market data was consolidated and added to detailed inputs, analyzed, and presented in this report.
Data Triangulation
After arriving at the overall market size of the global sepsis diagnostics market through the methodology mentioned above, this market was split into several segments and subsegments. The data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact market value data for critical segments and subsegments. The extrapolated market data was triangulated by studying various macro indicators and regional trends from both the demand- and supply-side participants.
Report Objectives
- To define, describe, and forecast the sepsis diagnostics market based on technology, product, method, pathogen, test type, end user and region
- To provide detailed information on the major factors influencing the market growth (such as drivers, restraints, opportunities, and industry-specific challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and their contributions to the overall sepsis diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the market value of various segments and subsegments for five regionsNorth America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the sepsis diagnostics market and comprehensively analyze their global revenue shares and core competencies
- To track and analyze competitive market-specific developments such as product launches/approvals and enhancements; partnerships, collaborations, agreements; expansions; and acquisitions
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the companys specific needs. The following customization options are available for the sepsis diagnostics market report:
- Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of the five major companies
- Company Information: Detailed analysis and profiling of additional market players (Up to 5)
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Sepsis Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Growth opportunities and latent adjacency in Sepsis Diagnostics Market
Have you not heard of T2 Biosystems rapid diagnostics direct from blood? Much faster than blood cultures, which is vital considering how quickly sepsis kills. FDA and CMS labeled it "breakthrough technology" and CMS subsidizes the test at 65, $97.